Unknown PHASE2 INTERVENTIONAL 2-arm NCT03145285

Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma (ABACUS)

Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Conditions Adrenocortical Carcinoma Cushing Syndrome

Updated 7 times since 2017 Last updated: May 9, 2017 Started: Apr 18, 2017 Primary completion: Apr 18, 2020 Completion: Apr 18, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Adrenocortical Carcinoma and Cushing Syndrome, this trial is ongoing. The trial is conducted by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia and has accumulated 7 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE2
May 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2

▶ Show 2 earlier versions

Jun 2018 — May 2020 [monthly]

Active Not Recruiting PHASE2
Jun 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

First recorded

Apr 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Niguarda Hospital
San Camillo Hospital, Rome
San Luigi Gonzaga Hospital

Data source: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brescia, Italy